Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2024-03-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of guarantees provided by the company for its subsidiaries. It details the guarantee contract, the amount, the parties involved, and the board's approval and opinion on the guarantee. It includes financial data of the subsidiary but does not contain comprehensive financial statements or a full financial report. The document is a specific corporate announcement about financing guarantees rather than a full financial report, earnings release, or regulatory filing. It fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees.
2024-03-29 Chinese
关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from 普洛药业股份有限公司 regarding the shareholding details of the top ten shareholders and top ten unrestricted shareholders as of a specific date (2024-03-27). It references a previously approved share repurchase plan and provides detailed shareholding data. The content focuses on shareholding structure related to a share buyback but does not report financial results, management changes, or other report types. It is not a full financial report or earnings release but an announcement related to shareholding in the context of a share repurchase. This fits the category of Transaction in Own Shares (POS), which covers company announcements about share repurchases and related shareholding information.
2024-03-28 Chinese
关于公司控股股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the company's controlling shareholder. It details the number of shares pledged, the proportion of total shares, pledge start and end dates, and assurances about the absence of risks affecting control or operations. There are no financial statements, earnings data, or management discussion. The document is a regulatory disclosure about share pledge activity, which fits the category of Regulatory Filings (RNS) as it is a compliance announcement about share pledge status and related risks, not a financial report or capital raising event.
2024-03-28 Chinese
关于回购股份的报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed report about the company's plan to repurchase its own shares, including the purpose, conditions, pricing, quantity, funding source, implementation period, risk factors, and authorization details. It discusses the board meeting approval and regulatory compliance related to the share buyback. The content focuses on the share repurchase plan and its specifics rather than announcing financial results or other report types. This matches the definition of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares. The document length is over 5,000 characters and contains substantive details about the repurchase plan, not just an announcement or summary, so it is not an RPA or RNS. Therefore, the correct classification is POS with high confidence.
2024-03-28 Chinese
关于回购公司股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 普洛药业股份有限公司 regarding a share repurchase plan. It details the purpose, amount, price limits, funding source, implementation period, and risks associated with the company's plan to buy back its own shares for an employee stock ownership plan. The document includes specific financial figures, authorization details, and risk disclosures related to the share repurchase. There is no indication that this is a full financial report, earnings release, or regulatory certification. The content clearly focuses on the company's share buyback activity, which fits the definition of a Transaction in Own Shares (POS) filing. The document length and detail confirm it is the announcement itself, not just a brief notice or report publication announcement.
2024-03-27 Chinese
第九届董事会第五次会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement of a board meeting resolution by 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.). It details the board's approval of a share repurchase (buyback) plan, including specifics on the price, amount, and timeline. The text includes voting results and confirms compliance with company law and articles of association. There are no financial statements or detailed financial performance data, nor is this an earnings release or annual/interim report. The content clearly relates to a transaction involving the company's own shares (share repurchase). Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused on the share buyback resolution, not a report publication or regulatory filing. Confidence is high due to clear keywords like '回购公司股份方案' (share repurchase plan) and voting results on this matter.
2024-03-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.